BDX · 10-Q · 2026Q2 · Full report
FDA El Paso Warning Letter
BECTON DICKINSON & CO · 2026-08-06 · Importance 44 · Surprise 60 · In source text
On April 30, 2026, BD’s El Paso manufacturing facility received a Warning Letter from the FDA’s Center for Drug Evaluation and Research following an October 2025 inspection of drug-device combination products, including ChloraPrep and PurPrep. The FDA cited deficiencies involving investigations, laboratory controls, sterility assurance, equipment cleaning, contamination control, facility design, terminal sterilization, and Quality Unit effectiveness. BD committed to corrective and preventive actions, including independent quality assessments and certain product recalls, and recorded a liability for estimated future response costs; the accrued liability could be insufficient. Until compliance is confirmed, the FDA may withhold Export Certificates and approval of new applications or supplements listing the El Paso site, and could pursue additional actions including seizure, injunction, or a consent decree.
Key facts
- As part of its response to the El Paso Warning Letter, BD committed to implementing additional corrective and preventive actions, including independent quality assessments and certain product recalls. source
- BD’s El Paso manufacturing facility received a Warning Letter from the FDA’s Center for Drug Evaluation and Research on April 30, 2026 following an October 2025 Drug Quality Assurance inspection. source
- The El Paso Warning Letter cited deficiencies including inadequate investigation of deviations, complaints, and out-of-specification results; insufficient laboratory controls and verification activities; and shortcomings in equipment cleaning, contamination control, and facility design. source
- The Warning Letter raised FDA concerns regarding repeat observations, terminal sterilization processes, and the authority and effectiveness of the Quality Unit. source
- Until the observations are completely addressed and the FDA confirms the site’s compliance, the FDA is likely to withhold the issuance of Export Certificates on drug or drug-led combination products manufactured at the El Paso site and withhold approval of new applications or supplements that list the site as a drug manufacturer. source
- BD received a Warning Letter from the FDA on November 22, 2024 limited to CareFusion 303, Inc.’s Dispensing quality management system and BD Pyxis products, and BD recorded a liability for estimated future costs associated with certain actions required to respond to the Dispensing Warning Letter. source
- The Warning Letter related to drug-device combination products manufactured at the El Paso site, including ChloraPrep and PurPrep. source
- BD submitted a comprehensive response to the FDA addressing the matters identified in the El Paso Warning Letter. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| operating_income | negative | committed | — | As part of its response to the El Paso Warning Letter, BD committed to implementing additional corrective and preventive actions,… |
| operating_income | negative | contingent | — | BD’s El Paso manufacturing facility received a Warning Letter from the FDA’s Center for Drug Evaluation and Research on April 30, 2026… |
| revenue | negative | contingent | — | Until the observations are completely addressed and the FDA confirms the site’s compliance, the FDA is likely to withhold the issuance of… |